<DOC>
	<DOCNO>NCT01765296</DOCNO>
	<brief_summary>- 6-week Efficacy Study The objective study prove safety non-inferiority analgesic efficacy CG100649 2 mg vs. celecoxib 200 mg , analgesic superiority CG100649 2 mg vs. placebo , administer day patient osteoarthritis hip knee 6 week Treatment period . The primary efficacy parameter difference Baseline Week 6 Western Ontario McMaster Universities Index Osteoarthritis ( WOMAC ) -Pain subscale . - Extended Safety Study The objective Extended Safety Study collect total 24 week safety data CG100649 include initial 6 week safety data , additional 18 week safety data subject agree consent form continue Extended Safety Study . Subjects administer CG100649 2 mg 18 week Extended Safety Study .</brief_summary>
	<brief_title>Phase III Study CG100649 Osteoarthritis Patients</brief_title>
	<detailed_description>1 . Number Subjects : 350 ( 2:2:1 ratio experimental vs. active comparator vs. placebo comparator ) 2 . Adverse Events cod preferred term body system use Medical Dictionary Regulatory Activities ( MedDRA )</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) 1 . Males female , age 20 year , able willing provide write informed consent 2 . Knee Hip OA diagnose accord American College Rheumatology guideline 3 . Chronic pain â‰¥3 month OA 4 . BP [ systolic 90140 mmHg , diastolic 5090 mmHg ] pulse rate [ rest 40100 bpm ] . 5 . WOMACPain score index joint must 48 010 numerical rating scale 6 . Blood chemistry must within 2x normal range 7 . Urinalysis must within normal limit ; minor deviation acceptable 8 . Subjects sexual partner must agree use double barrier contraception study period 3 month afterward , least one year post menopause , provide proof surgical sterility 9 . For prior nonsteroidal inflammatory drug ( NSAID ) user , subject history positive therapeutic benefit 10 . Subject willing limit alcohol intake 2 less drink per day study followup period 11 . Subjects must able read , understand follow study related document . Exclusion Criteria ( abbreviate ) 1 . Use analgesic except study medication acetaminophen time 2 . Use medication ongoing chronic symptom , psychiatric disorder could significantly diminish cognitive ability cause behavioral change would prevent subject comply study procedure . 3 . Subject legally incompetent , active psychosis , significant emotional problem sufficient interfere conduct study 4 . Use anticoagulant ( aspirin , warfarin , heparin , etc . ) within 2 week V1 5 . Previous history hypersensitivity allergy NSAIDs , COX2 inhibitor , carbonic anhydrase inhibitor , sulfa drug , aspirin , acetaminophen/paracetamol 6 . Subjects require knee hip arthroplasty within 2 month screen anticipate need surgical procedure index joint study 7 . Diagnosed treat active GI ulcer , GI bleeding , ulcerative colitis , severe renal , hepatic , coagulant disorder within 6 month prior randomization 8 . History nasal polyp , bronchospasm , urticaria , anaphylactic shock 9 . Subjects surgery affect joint within 6 month prior study subject prosthesis index joint 10 . Pregnant breastfeeding , expect conceive within project duration study 11 . Subjects currently participate participate clinical study within 4 week screen clinical trial evaluate NSAIDs COX2 inhibitor within 6 month screen 12 . Subjects receive even one dose rofecoxib etoricoxib time life 13 . History congestive heart failure status New York Heart Association IIIV , ischemic heart disease , uncontrolled hypertension , peripheral arterial disease , cerebrovascular disease subject one diseases 14 . Current user recreational illicit drug recent history ( 1 year ) drug alcohol abuse dependence 15 . History neoplastic disease chemotherapy within 5 year V1 , exception nonmetastatic skin cancer completely cure 16 . Subjects gout , pseudogout , inflammatory arthritis , Paget 's disease bone , chronic pain syndrome , fibromyalgia , another major joint disease 17 . Subjects use i.v , i.m. , oral corticosteroid , i.a . steroid hyaluronic acid injection within 1 month V1 18 . Subjects receive Chinese traditional arthritis treatment within 1 week V1 19 . Subjects suitable participate study investigator 's clinical decision</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>